Blood Cancer

MASTER: Dara-KRd in patients with multiple myeloma [Video]

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses findings from the Phase II MASTER trial (NCT03224507), which investigated daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) followed by autologous transplantation in patients with newly diagnosed multiple myeloma (MM). Patients additionally received Dara-KRd consolidation based on minimal residual disease (MRD) status, with the primary endpoint being MRD negativity. A majority of the cohort achieved a complete response and MRD negativity, but progression-free survival was lower in patients with ultra-high risk MM. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.